Response to the letter titled "The conundrum of the AD continuum"

Lutz Frolich; Wiesje M. van der Flier; Anders Gustavsson; Paolo M. Rossini; Drew Holzapfel

doi:https://doi.org/10.1002/alz.12784

Response to the letter titled "The conundrum of the AD continuum"

Lutz Frolich, Wiesje M. van der Flier, Anders Gustavsson, Paolo M. Rossini, Drew Holzapfel

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	373-374
Number of pages	2
Journal	Alzheimers & Dementia
Volume	19
Issue number	1
Early online date	8 Sept 2022
DOIs	https://doi.org/10.1002/alz.12784
Publication status	Published - Jan 2023

Access to Document

https://doi.org/10.1002/alz.12784

Cite this

@article{2ac09683029f469596d6148dc41f3484,

title = "Response to the letter titled {"}The conundrum of the AD continuum{"}",

author = "Lutz Frolich and {van der Flier}, {Wiesje M.} and Anders Gustavsson and Rossini, {Paolo M.} and Drew Holzapfel",

note = "Funding Information: Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA Inc., Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics. W.F. holds the Pasman chair. W.F. is recipient of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes‐Strijbisfonds. All funding is paid to her institution. W.F. has performed contract research for Biogen MA Inc., and Boehringer Ingelheim. All funding is paid to her institution. W.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. All funding is paid to her institution. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. All funding is paid to her institution. W.F. participated in advisory boards of Biogen MA Inc., and Roche. All funding is paid to her institution. W.F. was associate editor of Alzheimer, Research & Therapy in 2020/2021. W.F. is associate editor at Brain. Funding Information: This research is conducted on behalf of Project Alzheimer Value Europe (PAVE). PAVE is funded by Biogen and Roche. Author disclosures are available in the supporting information .",

year = "2023",

month = jan,

doi = "https://doi.org/10.1002/alz.12784",

language = "English",

volume = "19",

pages = "373--374",

journal = "Alzheimers & Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Response to the letter titled "The conundrum of the AD continuum"

AU - Frolich, Lutz

AU - van der Flier, Wiesje M.

AU - Gustavsson, Anders

AU - Rossini, Paolo M.

AU - Holzapfel, Drew

N1 - Funding Information: Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA Inc., Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics. W.F. holds the Pasman chair. W.F. is recipient of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes‐Strijbisfonds. All funding is paid to her institution. W.F. has performed contract research for Biogen MA Inc., and Boehringer Ingelheim. All funding is paid to her institution. W.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. All funding is paid to her institution. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. All funding is paid to her institution. W.F. participated in advisory boards of Biogen MA Inc., and Roche. All funding is paid to her institution. W.F. was associate editor of Alzheimer, Research & Therapy in 2020/2021. W.F. is associate editor at Brain. Funding Information: This research is conducted on behalf of Project Alzheimer Value Europe (PAVE). PAVE is funded by Biogen and Roche. Author disclosures are available in the supporting information .

PY - 2023/1

Y1 - 2023/1

UR - http://www.scopus.com/inward/record.url?scp=85137438279&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/alz.12784

DO - https://doi.org/10.1002/alz.12784

M3 - Letter

C2 - 36074640

SN - 1552-5260

VL - 19

SP - 373

EP - 374

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

IS - 1

ER -

Response to the letter titled "The conundrum of the AD continuum"

Access to Document

Other files and links

Cite this